Business Description
Lavipharm SA
ISIN : GRS246003008
Compare
Compare
Traded in other countries / regions
LAVI.GreeceBXA0.Germany IPO Date
1995-11-08Description
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes innovative, safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 0.76 | |||||
| Debt-to-EBITDA | 3.28 | |||||
| Interest Coverage | 1.84 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.68 | |||||
| Beneish M-Score | -2.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.2 | |||||
| 3-Year EBITDA Growth Rate | -45.9 | |||||
| 3-Year EPS without NRI Growth Rate | -56 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.76 | |||||
| 9-Day RSI | 71.01 | |||||
| 14-Day RSI | 67.47 | |||||
| 6-1 Month Momentum % | 21.55 | |||||
| 12-1 Month Momentum % | 106.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 0.86 | |||||
| Cash Ratio | 0.24 | |||||
| Days Inventory | 170.49 | |||||
| Days Sales Outstanding | 129.9 | |||||
| Days Payable | 123.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -109.4 | |||||
| Shareholder Yield % | 1.54 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.55 | |||||
| Operating Margin % | 8.21 | |||||
| Net Margin % | 3.67 | |||||
| FCF Margin % | -7.53 | |||||
| ROE % | 4.47 | |||||
| ROA % | 1.62 | |||||
| ROIC % | 2.86 | |||||
| ROC (Joel Greenblatt) % | 22.24 | |||||
| ROCE % | 7.6 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 122.38 | |||||
| PE Ratio without NRI | 163.17 | |||||
| PS Ratio | 3.23 | |||||
| PB Ratio | 3.85 | |||||
| Price-to-Operating-Cash-Flow | 489.5 | |||||
| EV-to-EBIT | 34.14 | |||||
| EV-to-EBITDA | 19.09 | |||||
| EV-to-Revenue | 3.69 | |||||
| EV-to-FCF | -49.08 | |||||
| Earnings Yield (Greenblatt) % | 2.92 | |||||
| FCF Yield % | -2.33 | |||||
| Forward Rate of Return (Yacktman) % | -44.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lavipharm SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 50.929 | ||
| EPS (TTM) (€) | 0.008 | ||
| Beta | 1.11 | ||
| Volatility % | 42.37 | ||
| 14-Day RSI | 67.47 | ||
| 14-Day ATR (€) | 0.034332 | ||
| 20-Day SMA (€) | 0.90205 | ||
| 12-1 Month Momentum % | 106.34 | ||
| 52-Week Range (€) | 0.427 - 1.01 | ||
| Shares Outstanding (Mil) | 167.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lavipharm SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lavipharm SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lavipharm SA Frequently Asked Questions
What is Lavipharm SA(ATH:LAVI)'s stock price today?
The current price of ATH:LAVI is €0.98. The 52 week high of ATH:LAVI is €1.01 and 52 week low is €0.43.
When is next earnings date of Lavipharm SA(ATH:LAVI)?
The next earnings date of Lavipharm SA(ATH:LAVI) is .
Does Lavipharm SA(ATH:LAVI) pay dividends? If so, how much?
Lavipharm SA(ATH:LAVI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers